Abbott Diagnostics on Thursday said the U.S Food and Drug Administration (FDA) had cleared a new diagnostic test for ovarian cancer.
The company said its first automated test for Architect HE4 uses a simple blood test to help in monitoring the recurrence or progression of this disease.
Search Senior Housing Facilities
Create a personal senior housing list with our search. Search Nursing Homes to find U.S. News-rated facilities. For other types of senior housing, you can access Seniors for Living's list of thousands of additional facilities.
| or |
Abbott has partnered with Fujirebio Diagnostics Inc to develop Architect HE4 assay that is approved for use in Europe, and other countries in Asia Pacific and Latin America.
Ovarian cancer is the fifth-leading cause of cancer death among women in the United States and affected nearly 22,000 women last year. Women who are at the post-menopausal stage are at the greatest risk of ovarian cancer.
Epithelial ovarian cancer, which accounts for about 85 percent to 90 percent of all ovarian cancers, is the most common type of ovarian cancer and begins from the cells that cover the surface of the ovary.
Follow us
